Menu
Not yet recruiting NCT07328724

Critical Illness After Hematopoietic Cell Transplantation

— Observational Critical Illness Ventilated Patients Hematopoetic Stem Cell Transplantation Transplant Complication

For patients and families

In plain language

Fill the application

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Critical Illness, Ventilated Patients, Hematopoetic Stem Cell Transplantation, Transplant Complication. Basic parameters: No limits · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Critical Illness Among Recipients of Hematopoietic Cell Transplantation (CARE-HCT): a Prospective, Multicenter Observational Study in China

Overview

This is a prospective, multicenter observational trial for patients who develop critical illness after hematopoietic cell transplantation. Patients who are admitted to the intensive care unit after undergoing hematopoietic cell transplantation at the participating medical centers will be enrolled in this study. The clinical characteristics, laboratory profiles, managements, and clinical outcomes will be prospectively collected.

Primary outcome measures

  • Overall survival [Time frame: Before ICU discharge; within 6 months after ICU discharge; and within 1 year after ICU discharge.]
Secondary outcome measures (6)
  • Non-relapse mortality [Time frame: Before ICU discharge; within 6 months after ICU discharge; and within 1 year after ICU discharge.]
  • Relapse [Time frame: At ICU admission and within 1 year of ICU discharge.]
  • Transplant complication [Time frame: At ICU admission and within 1 year of ICU discharge.]
  • Organ failure [Time frame: At ICU admission and within 1 year of ICU discharge.]
  • Organ support therapy [Time frame: At ICU admission and within 1 year after ICU discharge.]
  • Long-term survival data [Time frame: Up to 5 years after ICU discharge.]

Eligibility criteria

Inclusion criteria

  • Patients who underwent hematopoietic cell transplantation at any of the participating medical centers.
  • Patients who are admitted to ICU for the management of critical illness following hematopoietic cell transplantation.

Exclusion criteria

  • Admitted to ICU for a reason other than critical illness (e.g., routine postoperative monitoring) and discharged within 2 days of ICU admission.
  • Unavailable in-ICU clinical outcomes or absent key baseline characteristics.
  • Any other conditions that, in the opinion of the investigator, can interfere with the interpretation of data.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

China · 6 centers
  • Peking University People's Hospital — Beijing
  • Xinqiao hospital of the third military medical university — Chongqing
  • First Affiliated Hospital of Zhejiang University — Hangzhou
  • First Affiliated Hospital of Harbin Medical University — Harbin
  • Hematology Hospital of Chinese Academy of Medical Sciences — Tianjin
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology — Wuhan

Identifiers

NCT: NCT07328724 · 2025-z259

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗